Expression and clinical significance of cancerous inhibitor of protein phosphatase 2A （CIP2A） in human ovarian cancers tissues.

doi:10.7504/fk2015050117

Abstract

Abstract:

Abstract： Objective To investigate expression and clinical significance of CIP2A in ovarian cancer tissues.

Key words: CIP2A, ovarian cancer, tumor grade

摘要：

目的探讨CIP2A在卵巢癌组织中的表达情况和临床意义。方法选取2008年1月至2010年7月在中国医科大学附属盛京医院手术切除的卵巢癌组织77例及正常卵巢组织6例，并收集其临床病理特征。采用兔抗人CIP2A多克隆抗体以SP免疫组化法、实时定量PCR进行研究，并分析CIP2A表达与临床病理因素的关系。结果在6例正常卵巢组织中，CIP2A的表达为阴性或低表达；而在77例卵巢癌组织中，33.77% （26/77）具有CIP2A 阳性表达。CIP2A在卵巢浆液性癌、子宫内膜样癌、黏液性癌和透明细胞癌中的阳性表达率分别为39.13% （18/46）、23.53%（4/17）、16.67% （2/12）和 100% （2/2）。CIP2A的表达与卵巢癌病理分期和肿瘤病理分级有关。实时定量PCR结果证实，相比正常卵巢组织，卵巢癌组织CIP2A转录水平显著提高（P<0.05）。结论 CIP2A在卵巢癌中高表达并且与FIGO分期和肿瘤病理分级有关。CIP2A可能成为卵巢癌诊断的新指标和治疗中的新靶点。

关键词: CIP2A, 卵巢癌, 肿瘤病理分级

CLC Number:

R737.3

LI Zheng-tao，FANG Yuan-yuan.. Expression and clinical significance of cancerous inhibitor of protein phosphatase 2A （CIP2A） in human ovarian cancers tissues.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015050117.

李正涛，方媛媛. CIP2A在卵巢癌组织中的表达及其临床意义研究[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2015050117.

References

［1］ Junttila MR，Puustinen P，Niemelä M，et al. CIP2A inhibits PP2A in human malignancies［J］. Cell，2007，130（1）: 51-62.

［2］ Dong QZ，Wang Y，Dong XJ，et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis［J］. Ann Surg Oncol，2011，18（3）: 857-865.

［3］ Côme C，Laine A，Chanrion M，et al.CIP2A is associated with human breast cancer aggressivity［J］. Clin Cancer Res，2009，15（16）: 5092-5100.

［4］ Böckelman C，Hagström J，Mäkinen LK，et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer［J］. Br J Cancer，2012，104（12）: 1890-1895.

［5］ Guo Z，Liu D，Su Z. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway［J］. Tumour Biol，2015，［Epub ahead of print］

［6］ Huang J，Jia J，Tong Q，et al. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy［J］. Tumour Biol，2015,36(3):1589-1594.

［7］ Schwartz DR，Kardia SL，Shedden KA，et al. Gene expression in ovarian cancer reflects both morphology and biological behavior，distinguishing clear cell from other poor-prognosis ovarian carcinomas［J］. Cancer Res，2002，62（16）: 4722-4729.

［8］ Zorn KK，Bonome T，Gangi L，et al. Gene expression profiles of serous，endometrioid，and clear cell subtypes of ovarian and endometrial cancer［J］. Clin Cancer Res，2005，11（18）: 6422-6430.

［9］. De P，Carlson J，Leyland-Jones B，et al. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A （CIP2A）: an oncoprotein with many hands［J］. Oncotarget，2014，5（13）:4581-4602.

［10］ Kim A，Ueda Y，Naka T，et al. Therapeutic strategies in epithelial ovarian cancer［J］. J Exp Clin Cancer Res，2012，31: 14.

（2015-01-03收稿 2015-03-20修回）

[1]	LI Yi-fan, LI Ning, WU Ling-ying. Treatment for recurrent platinum-resistant epithelial ovarian carcinoma. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(5): 503-507.
[2]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(3): 301-309.
[3]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(3): 310-318.
[4]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(1): 56-65.
[5]	CAO Dong-yan, XIANG Yang. Quality control of surgery for ovarian cancer. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(1): 29-32.
[6]	. [J]. Acta Metallurgica Sinica, 2021, 37(8): 826-831.
[7]	. [J]. Acta Metallurgica Sinica, 2021, 37(6): 601-604.
[8]	GAO Qing-lei. Ovarian cancer and normalization of gene detection. [J]. Acta Metallurgica Sinica, 2021, 37(6): 605-609.
[9]	HUANG He，FENG Yan-ling，LIU Ji-hong. Primary and interval cytoreductive surgery for ovarian cancer. [J]. Acta Metallurgica Sinica, 2021, 37(6): 609-613.
[10]	DOU Sha，LI Yi，CUI Heng. First-line chemotherapy for newly diagnosed epithelial ovarian cancer. [J]. Acta Metallurgica Sinica, 2021, 37(6): 613-616.
[11]	CHEN Yu-lian，SHI Ting-yan，ZANG Rong-yu. Problems related to surgery for platinum-sensitive relapsed ovarian cancer and standardized diagnosis and treatment. [J]. Acta Metallurgica Sinica, 2021, 37(6): 616-620.
[12]	DENG Li，LIANG Zhi-qing. Application and controversy of minimally invasive surgery in the treatment of ovarian cancer. [J]. Acta Metallurgica Sinica, 2021, 37(6): 620-623.
[13]	YUAN Zeng，SONG Kun，KONG Bei-hua. Problems related to bilateral salpingo-oophorectomy for hereditary ovarian cancer and the controversy. [J]. Acta Metallurgica Sinica, 2021, 37(6): 623-627.
[14]	MENG Yuan-guang，YE Ming-xia. Complications of cytoreductive surgery for ovarian cancer and the prevention and treatment. [J]. Acta Metallurgica Sinica, 2021, 37(6): 627-630.
[15]	JIANG Fang，XIANG Yang. Current status and progress of immunotherapy for ovarian cancer. [J]. Acta Metallurgica Sinica, 2021, 37(6): 630-634.